CollPlant announced positive final clinical trial results for Vergenix™STR, intended for the treatment of tendinopathy. The company submitted its technical file in late 4Q15 in anticipation of CE Mark approval in 2Q16.
The objective of the Company’s prospective, open label, single arm trial was to demonstrate safety and performance of VergenixSTR in 20 patients suffering from tennis elbow. All patients were followed for six months, and performance compared very favorably to published results of standard-of-care therapies. (Three month results were reported in 4Q15.)
CollPlant announced positive final clinical trial results for Vergenix™STR, intended for the treatment of tendinopathy. The company submitted its technical file in late 4Q15 in anticipation of CE Mark approval in 2Q16.
The objective of the Company's prospective, open label, single arm trial was to demonstrate safety and performance of...
CollPlant announced positive final clinical trial results for Vergenix™STR, intended for the treatment of tendinopathy. The company submitted its technical file in late 4Q15 in anticipation of CE Mark approval in 2Q16.
The objective of the Company’s prospective, open label, single arm trial was to demonstrate safety and performance of VergenixSTR in 20 patients suffering from tennis elbow. All patients were followed for six months, and performance compared very favorably to published results of standard-of-care therapies. (Three month results were reported in 4Q15.)
Copy to clipboard 
